New Zealand health manufacturing revenue rises 55%

New Zealand's health manufacturing sector recorded a sharp rise in revenue in Unleashed's Q2 2026 Manufacturing Health Index, outperforming much of the wider manufacturing market.

Health manufacturers generated NZD $381,110 in sales revenue, up 55% year on year, according to the index. Gross margins rose 11% to 40%, making health one of only two New Zealand manufacturing sectors tracked by Unleashed to post growth in both revenue and margins over the period.

The figures also pointed to a more restrained approach to stock purchasing. Stock on hand fell 6% to NZD $138,641, while purchase orders dropped 62%, suggesting businesses held back on new buying even as sales and margins improved.

The contrast with Australia was stark. In the same quarter, Australian health manufacturing revenue fell 45% year on year, while margins declined 39%.

Mixed signals

Jarrod Adam, Head of Product for Production and Distribution at Unleashed, said the figures showed why revenue alone does not give a full picture of sector conditions.

"New Zealand's health manufacturers are delivering a strong performance on the surface, with revenue up 55% year on year. However, the 62% decline in purchase orders suggests businesses could still be cautious about what comes next.

"The gap between current performance and future purchasing is particularly interesting. Manufacturers may be generating stronger returns from existing demand and inventory, while taking a more measured approach to committing cash to new stock until they have greater certainty about future requirements.

"It's a reminder that revenue growth doesn't necessarily translate into increased purchasing. A business can be performing strongly today while deliberately taking a more conservative approach to replenishment, particularly where inventory, supplier costs and working capital are under close scrutiny.

"For health manufacturers, maintaining that balance will be important. Strong demand needs to be matched with the right inventory at the right time, without tying up unnecessary capital in stock that may take longer to move.

The key is having visibility across sales, orders, inventory and purchasing activity. That allows manufacturers to distinguish between a genuine change in demand and a temporary shift in purchasing behaviour, and to make more informed decisions about when and how much to replenish."

The data arrives as New Zealand's health technology ecosystem continues to expand. The Ministry of Business, Innovation and Employment has identified the country's medical technology segment as an area with potential to support higher-value exports.

Domestic demand may also be strengthening. Census data showed New Zealand's median age rose to 38 in 2023 from 37 in 2018, pointing to an ageing population that could increase demand for health-related products over time.

Inventory focus

The fall in stock on hand was modest compared with the drop in purchase orders, suggesting some manufacturers may be relying on existing inventory and current sales momentum rather than building larger stock positions. That approach can help preserve cash, especially when input costs and working capital remain under pressure.

At the same time, lower replenishment raises questions about how long current inventory levels can support growth if demand remains firm. Manufacturers may need to judge carefully whether the reduction in purchasing reflects efficiency, caution or uncertainty about future orders.

Unleashed's index tracks indicators including revenue, gross margin, stock on hand and purchase orders across manufacturing categories. In New Zealand health manufacturing, the combination of higher sales, stronger margins and lower purchasing points to a sector that is expanding while remaining guarded about near-term commitments.

That mix sets health manufacturing apart from broader signs of strain across parts of the region's industrial economy and from the weaker performance reported in Australia. For now, the numbers show a sector lifting returns while keeping a tighter hold on inventory spending.